When it comes to the five biotech penny stocks to watch this quarter highlighted in today’s article, the author emphasizes that “These aren’t just names… Read More »There’s Good Reason To Watch These 5 Biotech Penny Stocks This Quarter
While large-cap biotech stocks may come with less risk than their small-cap counterparts, the author of today’s article notes that “On the plus side small-cap… Read More »10 Under $10: The Best Small-Cap Biotech Stocks For 2021
Among the three biotech stocks to watch going forward in 2021 highlighted by the author of today’s article is a specialty company focused on developing… Read More »3 Biotech Stocks To Watch – Including A Pioneering CBD Company
When it comes to investing in biotech stocks, the author of today’s article points out that “By identifying companies that are likely to report rapid… Read More »On The Cusp Of Commercializing Its First Drug, Now May Be The Time To Buy This Biotech Stock
The final week of January was yet another big one for biotech, with perhaps the most important development of the week being phase III trial results for Novavax’s COVID-19 vaccine.
The genomic revolution in underway, with the author of today’s article noting that “artificial intelligence is converging with decades of breakthrough genomics research to create a new generation of hyper-efficient, hyper-accurate, and hyper-precise gene editing medicines.”
As January comes to a close, which biotech stocks await FDA decisions in February that could serve as catalysts?
When it comes to the performance of healthcare companies during the pandemic, the author of today’s article notes that “Those best prepared for developing a… Read More »This Biotech Laggard Could Offer Traders A Market-Beating Opportunity
“Investors who want the massive potential gains from penny stock investing should focus on those with a real business producing real cash,” advise the authors… Read More »“Real Businesses Producing Real Cash”: 3 Penny Stocks Poised To Benefit From Major Market Trends
Over the course of the past 12 months, Novavax has gone from penny stock status before the pandemic to skyrocketing more than 2,700% over the course of the pandemic thus far.